Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
ABSTRACT Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment choice for advanced non‐small cell lung cancer (NSCLC) patients with EGFR mutations. EGFR‐TKIs have made significant progress in the treatment of advanced NSCLC patients, but drug resistance i...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | The Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/crj.70037 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|